473 related articles for article (PubMed ID: 19559113)
21. Suitability of MDCK cells grown in a serum-free medium for influenza virus production.
Kessler N; Thomas-Roche G; Gérentes L; Aymard M
Dev Biol Stand; 1999; 98():13-21; discussion 73-4. PubMed ID: 10494956
[TBL] [Abstract][Full Text] [Related]
22. Suspension-Vero cell cultures as a platform for viral vaccine production.
Paillet C; Forno G; Kratje R; Etcheverrigaray M
Vaccine; 2009 Oct; 27(46):6464-7. PubMed ID: 19559123
[TBL] [Abstract][Full Text] [Related]
23. Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines.
Kalbfuss B; Genzel Y; Wolff M; Zimmermann A; Morenweiser R; Reichl U
Biotechnol Bioeng; 2007 May; 97(1):73-85. PubMed ID: 16921531
[TBL] [Abstract][Full Text] [Related]
24. Genetic engineering of live attenuated influenza viruses.
Jin H; Chen Z; Liu J; Kemble G
Methods Mol Biol; 2012; 865():163-74. PubMed ID: 22528159
[TBL] [Abstract][Full Text] [Related]
25. Mathematical model of influenza A virus production in large-scale microcarrier culture.
Möhler L; Flockerzi D; Sann H; Reichl U
Biotechnol Bioeng; 2005 Apr; 90(1):46-58. PubMed ID: 15736163
[TBL] [Abstract][Full Text] [Related]
26. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
Genzel Y; Fischer M; Reichl U
Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
[TBL] [Abstract][Full Text] [Related]
27. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.
Rourou S; van der Ark A; van der Velden T; Kallel H
Vaccine; 2007 May; 25(19):3879-89. PubMed ID: 17307281
[TBL] [Abstract][Full Text] [Related]
28. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.
Wressnigg N; Voss D; Wolff T; Romanova J; Ruthsatz T; Mayerhofer I; Reiter M; Nakowitsch S; Humer J; Morokutti A; Muster T; Egorov A; Kittel C
Vaccine; 2009 May; 27(21):2851-7. PubMed ID: 19366569
[TBL] [Abstract][Full Text] [Related]
29. A cell-based backup to speed up pandemic influenza vaccine production.
Lee MS; Hu AY
Trends Microbiol; 2012 Mar; 20(3):103-5. PubMed ID: 22257962
[TBL] [Abstract][Full Text] [Related]
30. MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high titres.
van Wielink R; Harmsen MM; Martens DE; Peeters BP; Wijffels RH; Moormann RJ
Vaccine; 2011 Sep; 29(40):6976-85. PubMed ID: 21787829
[TBL] [Abstract][Full Text] [Related]
31. Live cold-adapted influenza A vaccine produced in Vero cell line.
Romanova J; Katinger D; Ferko B; Vcelar B; Sereinig S; Kuznetsov O; Stukova M; Erofeeva M; Kiselev O; Katinger H; Egorov A
Virus Res; 2004 Jul; 103(1-2):187-93. PubMed ID: 15163508
[TBL] [Abstract][Full Text] [Related]
32. Mosquito and mammalian cells grown on microcarriers for four-serotype dengue virus production: variations in virus titer, plaque morphology, and replication rate.
Liu CC; Wu SC
Biotechnol Bioeng; 2004 Mar; 85(5):482-8. PubMed ID: 14760688
[TBL] [Abstract][Full Text] [Related]
33. Capture of cell culture-derived influenza virus by lectins: strain independent, but host cell dependent.
Opitz L; Zimmermann A; Lehmann S; Genzel Y; Lübben H; Reichl U; Wolff MW
J Virol Methods; 2008 Dec; 154(1-2):61-8. PubMed ID: 18840469
[TBL] [Abstract][Full Text] [Related]
34. Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production.
Coussens PM; Smith KA; Weber PS; Colvin CJ
Vaccine; 2011 Nov; 29(47):8661-8. PubMed ID: 21911025
[TBL] [Abstract][Full Text] [Related]
35. Generation and characterization of reassortant influenza A viruses propagated in serum-free cultured MDCK-SF1 cells.
Voeten JT; Claas EC; Brands R; Palache AM; van Scharrenburg GJ; Rimmelzwaan GF; Osterhaus AD
Dev Biol Stand; 1999; 98():77-87; discussion 89-90. PubMed ID: 10494961
[TBL] [Abstract][Full Text] [Related]
36. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Barrett PN; Mundt W; Kistner O; Howard MK
Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
[TBL] [Abstract][Full Text] [Related]
37. [Use of plant-origin components in roller cultivation of vaccine reassortant influenza virus strain H5N2].
Mazurkova NA; Desheva IuA; Shishkina LN; Stavskiĭ EA; Rudenko LG
Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):88-92. PubMed ID: 21598624
[TBL] [Abstract][Full Text] [Related]
38. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
[TBL] [Abstract][Full Text] [Related]
39. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
[TBL] [Abstract][Full Text] [Related]
40. Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine.
Brands R; Visser J; Medema J; Palache AM; van Scharrenburg GJ
Dev Biol Stand; 1999; 98():93-100; discussion 111. PubMed ID: 10494962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
